Cytokeratin 14, Monoclonal Antibody

For Research Use Only. Not for use in diagnostic procedures.

Monoclonal

IgG3

LL002

Mouse

Cytokeratin 14 is a mouse monoclonal antibody derived from cell culture supernatant that is concentrated, dialyzed, filter sterilized and diluted in buffer pH 7.5, containing BSA and sodium azide as a preservative.

Store at 2 to 8 degree C in the dark.

Manufactured in an ISO 13485:2016 Certified Laboratory.

Small volumes of anti-KRT14 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Cytokeratin 14 is a Type I polypeptide found in basal cells of squamous epithelia, some glandular epithelia, myoepithelium, and mesothelial cells. It is usually found as a heterotetramer with two cytokeratin 5 molecules, and a Type II keratin. Together, they form the cytoskeleton of epithelial cells. Mutations in the genes for these cytokeratins are associated with Epidermolysis Bullosa Simplex. Cytokeratin 14 has been studied as a prognostic marker in Breast Cancer. This antibody labels the basal layer of stratifying squamous and non-squamous epithelia. The staining pattern is cytoplasmic. It recognizes Basal Cell Carcinomas and Squamous Cell Carcinomas. Anti-CK14 has been demonstrated to be useful in differentiating Squamous Cell Carcinomas from other epithelial tumors. This antibody has also been useful in separating oncocytic tumors of the kidney from renal mimics, as well as in determining metaplastic Carcinomas of the Breast.

51,561 Da[Similar Products]

Keratin, type I cytoskeletal 14

CK-14; K14  [Similar Products]

K1C14_HUMAN

Function: The nonhelical tail domain is involved in promoting KRT5-KRT14 filaments to self-organize into large bundles and enhances the mechanical properties involved in resilience of keratin intermediate filaments in vitro. Ref.13

Subunit structure: Heterotetramer of two type I and two type II keratins. disulfide-linked keratin-14 associates with keratin-5. Interacts with TRADD and with keratin filaments. Associates with other type I keratins. Ref.12 Ref.13 Ref.16

Subcellular location: Cytoplasm. Nucleus. Note: Expressed in both as a filamentous pattern. Ref.13 Ref.16

Tissue specificity: Detected in the basal layer, lowered within the more apically located layers specifically in the stratum spinosum, stratum granulosum but is not detected in stratum corneum. Strongly expressed in the outer root sheath of anagen follicles but not in the germinative matrix, inner root sheath or hair. Found in keratinocytes surrounding the club hair during telogen. Ref.11

Post-translational modification: A disulfide bond is formed between rather than within filaments and promotes the formation of a keratin filament cage around the nucleus.

Involvement in disease: Epidermolysis bullosa simplex, Dowling-Meara type (DM-EBS) [MIM:131760]: A severe form of intraepidermal epidermolysis bullosa characterized by generalized herpetiform blistering, milia formation, dystrophic nails, and mucous membrane involvement.Note: The disease is caused by mutations affecting the gene represented in this entry.Epidermolysis bullosa simplex, Weber-Cockayne type (WC-EBS) [MIM:131800]: A form of intraepidermal epidermolysis bullosa characterized by blistering limited to palmar and plantar areas of the skin.Note: The disease is caused by mutations affecting the gene represented in this entry.Epidermolysis bullosa simplex, Koebner type (K-EBS) [MIM:131900]: A form of intraepidermal epidermolysis bullosa characterized by generalized skin blistering. The phenotype is not fundamentally distinct from the Dowling-Meara type, although it is less severe.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.9 Ref.10 Ref.17 Ref.19 Ref.28 Ref.29 Ref.31 Ref.32 Ref.33 Ref.41Epidermolysis bullosa simplex, autosomal recessive (AREBS) [MIM:601001]: An intraepidermal epidermolysis bullosa characterized by localized blistering on the dorsal, lateral and plantar surfaces of the feet.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.21Naegeli-Franceschetti-Jadassohn syndrome (NFJS) [MIM:161000]: A rare autosomal dominant form of ectodermal dysplasia. The cardinal features are absence of dermatoglyphics (fingerprints), reticular cutaneous hyperpigmentation (starting at about the age of 2 years without a preceding inflammatory stage), palmoplantar keratoderma, hypohidrosis with diminished sweat gland function and discomfort provoked by heat, nail dystrophy, and tooth enamel defects.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.39Dermatopathia pigmentosa reticularis (DPR) [MIM:125595]: A rare ectodermal dysplasia characterized by lifelong persistent reticulate hyperpigmentation, non-cicatricial alopecia, and nail dystrophy. Variable features include adermatoglyphia, hypohidrosis or hyperhidrosis, and palmoplantar hyperkeratosis.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.39

Miscellaneous: There are two types of cytoskeletal and microfibrillar keratin: I (acidic; 40-55 kDa) and II (neutral to basic; 56-70 kDa).

Sequence similarities: Belongs to the intermediate filament family.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.